Showing 1 - 3 results of 3 for search 'María E. Icaza-Chávez', query time: 0.02s Refine Results
  1. 1
    Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD)

    Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD) by Bryan A. Priego-Parra, Arturo Triana-Romero, Raúl Bernal-Reyes, María E. Icaza-Chávez, Sophia E. Martínez-Vázquez, Ana D. Cano-Contreras, Héctor Vivanco-Cid, José M. Remes-Troche

    Published 2024-02-01
    Get full text
    Article
  2. 2
    Hepatic Steatosis Index (HSI): A Valuable Biomarker in Subjects with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

    Hepatic Steatosis Index (HSI): A Valuable Biomarker in Subjects with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) by Bryan A. Priego-Parra, Arturo Triana-Romero, Génesis P. Martínez-Pérez, Sara A. Reyes-Diaz, Héctor R. Ordaz-Alvarez, Raúl Bernal-Reyes, María E. Icaza-Chávez, Sophia E. Martínez-Vázquez, Ana D. Cano-Contreras, Héctor Vivanco-Cid, José M. Remes-Troche

    Published 2024-02-01
    Get full text
    Article
  3. 3
    Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023

    Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023 by Linda E. Munoz-Espinosa, Aldo Torre, Laura Cisneros, Iaarah Montalvo-Gordon, René Malé-Velázquez, Scherezada Mejía, Juan Ramón Aguilar-Ramírez, Javier Lizardi-Cervera, María E. Icaza-Chávez, Frida Gasca-Díaz, Larissa Hernández-Hernández, Paula Cordero-Perez, Luis A. Chi-Cervera, Lilian Torres-Made, Fátima Rodríguez-Álvarez, Graciela Tapia, Jorge Luis Poo

    Published 2024-02-01
    Get full text
    Article

Search Tools: